{
  "id": 762838,
  "title": "Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients",
  "url": "https://urgent.news/2026/08/13/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-13T12:02:17.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b-2a-resolve-trial-including-new-data-on-odynophagia-painful-swallowing-in-eosinophilic-esophagitis-patients"
  },
  "original_language": "en",
  "account": null,
  "summary": "The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}